Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

Purpose: Advanced-stage mucinous ovarian carcinoma (MOC) has poor chemotherapy response and prognosis and lacks biomarkers to aid stage I adjuvant treatment. Differentiating primary MOC from gastrointestinal (GI) metastases to the ovary is also challenging due to phenotypic similarities. Clinicopathologic and gene-expression data were analyzed to identify prognostic and diagnostic features.

Experimental Design: Discovery analyses selected 19 genes with prognostic/diagnostic potential. Validation was performed through the Ovarian Tumor Tissue Analysis consortium and GI cancer biobanks comprising 604 patients with MOC (n = 333), mucinous borderline ovarian tumors (MBOT, n = 151), and upper GI (n = 65) and lower GI tumors (n = 55).

Results: Infiltrative pattern of invasion was associated with decreased overall survival (OS) within 2 years from diagnosis, compared with expansile pattern in stage I MOC [hazard ratio (HR), 2.77; 95% confidence interval (CI), 1.04-7.41, P = 0.042]. Increased expression of THBS2 and TAGLN was associated with shorter OS in MOC patients (HR, 1.25; 95% CI, 1.04-1.51, P = 0.016) and (HR, 1.21; 95% CI, 1.01-1.45, P = 0.043), respectively. ERBB2 (HER2) amplification or high mRNA expression was evident in 64 of 243 (26%) of MOCs, but only 8 of 243 (3%) were also infiltrative (4/39, 10%) or stage III/IV (4/31, 13%).

Conclusions: An infiltrative growth pattern infers poor prognosis within 2 years from diagnosis and may help select stage I patients for adjuvant therapy. High expression of THBS2 and TAGLN in MOC confers an adverse prognosis and is upregulated in the infiltrative subtype, which warrants further investigation. Anti-HER2 therapy should be investigated in a subset of patients. MOC samples clustered with upper GI, yet markers to differentiate these entities remain elusive, suggesting similar underlying biology and shared treatment strategies.

Citing Articles

A new method for network bioinformatics identifies novel drug targets for mucinous ovarian carcinoma.

Craig O, Lee S, Pilcher C, Saoud R, Abdirahman S, Salazar C NAR Genom Bioinform. 2024; 6(3):lqae096.

PMID: 39184376 PMC: 11344246. DOI: 10.1093/nargab/lqae096.

Therapeutic developments in pancreatic cancer.

Hu Z, OReilly E Nat Rev Gastroenterol Hepatol. 2023; 21(1):7-24.

PMID: 37798442 DOI: 10.1038/s41575-023-00840-w.

Update on Prognostic and Predictive Markers in Mucinous Ovarian Cancer.

Borella F, Mitidieri M, Cosma S, Benedetto C, Bertero L, Fucina S Cancers (Basel). 2023; 15(4).

PMID: 36831515 PMC: 9954175. DOI: 10.3390/cancers15041172.

Ciliated Cells in Ovarian Cancer Decrease with Increasing Tumor Grade and Disease Progression.

Richardson M, Recouvreux M, Karlan B, Walts A, Orsulic S Cells. 2022; 11(24).

PMID: 36552773 PMC: 9776429. DOI: 10.3390/cells11244009.

Profiling the immune landscape in mucinous ovarian carcinoma.

Meagher N, Hamilton P, Milne K, Thornton S, Harris B, Weir A Gynecol Oncol. 2022; 168:23-31.

PMID: 36368129 PMC: 10374276. DOI: 10.1016/j.ygyno.2022.10.022.

References

Zhou H, Fang Y, Weinberger P, Ding L, Cowell J, Hudson F . Transgelin increases metastatic potential of colorectal cancer cells in vivo and alters expression of genes involved in cell motility. BMC Cancer. 2016; 16:55. PMC: 4741053. DOI: 10.1186/s12885-016-2105-8. View

Schlappe B, Zhou Q, OCearbhaill R, Iasonos A, Soslow R, Abu-Rustum N . A descriptive report of outcomes of primary mucinous ovarian cancer patients receiving either an adjuvant gynecologic or gastrointestinal chemotherapy regimen. Int J Gynecol Cancer. 2019; 29(5):904-909. PMC: 7385730. DOI: 10.1136/ijgc-2018-000150. View

Busca A, Nofech-Mozes S, Olkhov-Mitsel E, Gien L, Bassiouny D, Mirkovic J . Histological grading of ovarian mucinous carcinoma - an outcome-based analysis of traditional and novel systems. Histopathology. 2019; 77(1):26-34. DOI: 10.1111/his.14039. View

Kramer P, Talhouk A, Brett M, Chiu D, Cairns E, Scheunhage D . Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clin Cancer Res. 2020; 26(20):5400-5410. DOI: 10.1158/1078-0432.CCR-20-1268. View

Gouy S, Saidani M, Maulard A, Bach-Hamba S, Bentivegna E, Leary A . Characteristics and Prognosis of Stage I Ovarian Mucinous Tumors According to Expansile or Infiltrative Type. Int J Gynecol Cancer. 2018; 28(3):493-499. DOI: 10.1097/IGC.0000000000001202. View

Wu X, Zhou C, Zhang Y, Yan R, Wei W, Chen X . Cancer-derived exosomal miR-221-3p promotes angiogenesis by targeting THBS2 in cervical squamous cell carcinoma. Angiogenesis. 2019; 22(3):397-410. DOI: 10.1007/s10456-019-09665-1. View

Gorringe K, Cheasley D, Wakefield M, Ryland G, Allan P, Alsop K . Therapeutic options for mucinous ovarian carcinoma. Gynecol Oncol. 2020; 156(3):552-560. PMC: 7056511. DOI: 10.1016/j.ygyno.2019.12.015. View

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E . Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022; 387(1):9-20. PMC: 10561652. DOI: 10.1056/NEJMoa2203690. View

Meagher N, Schuster K, Voss A, Budden T, Pang C, DeFazio A . Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. Gynecol Oncol. 2018; 150(3):527-533. DOI: 10.1016/j.ygyno.2018.07.013. View

10.

Shitara K, Bang Y, Iwasa S, Sugimoto N, Ryu M, Sakai D . Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020; 382(25):2419-2430. DOI: 10.1056/NEJMoa2004413. View

11.

Cassier P, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S . Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021; 15(1):101266. PMC: 8605190. DOI: 10.1016/j.tranon.2021.101266. View

12.

Hart W . Mucinous tumors of the ovary: a review. Int J Gynecol Pathol. 2005; 24(1):4-25. View

13.

Millstein J, Budden T, Goode E, Anglesio M, Talhouk A, Intermaggio M . Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020; 31(9):1240-1250. PMC: 7484370. DOI: 10.1016/j.annonc.2020.05.019. View

14.

Seidman J, Kurman R, Ronnett B . Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003; 27(7):985-93. DOI: 10.1097/00000478-200307000-00014. View

15.

Colombo N, Sessa C, Bois A, Ledermann J, McCluggage W, McNeish I . ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019; 29(4):728-760. DOI: 10.1136/ijgc-2019-000308. View

16.

Chay W, Chew S, Ong W, Busmanis I, Li X, Thung S . HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. PLoS One. 2013; 8(4):e61565. PMC: 3631219. DOI: 10.1371/journal.pone.0061565. View

17.

Sun Y, Peng W, He W, Luo M, Chang G, Shen J . Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer. J Exp Clin Cancer Res. 2018; 37(1):166. PMC: 6056937. DOI: 10.1186/s13046-018-0818-z. View

18.

Nan P, Dong X, Bai X, Lu H, Liu F, Sun Y . Tumor-stroma TGF-β1-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin αβ/CD36-mediated activation of the MAPK pathway. Cancer Lett. 2021; 528:59-75. DOI: 10.1016/j.canlet.2021.12.025. View

19.

Meagher N, Wang L, Rambau P, Intermaggio M, Huntsman D, Wilkens L . A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Mod Pathol. 2019; 32(12):1834-1846. PMC: 8207534. DOI: 10.1038/s41379-019-0302-0. View

20.

Kodama J, Hashimoto I, Seki N, Hongo A, Yoshinouchi M, Okuda H . Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor. Anticancer Res. 2001; 21(4B):2983-7. View